Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) MYC-rearranged lymphomas other than Burkitt: Comparison between R-CHOP and Burki...
Journal Information
Vol. 149. Issue 8.
Pages 339-342 (October 2017)
Download PDF
More article options
Vol. 149. Issue 8.
Pages 339-342 (October 2017)
Brief report
DOI: 10.1016/j.medcle.2017.09.011
MYC-rearranged lymphomas other than Burkitt: Comparison between R-CHOP and Burkitt-type immunochemotherapy
Linfomas con reordenamiento de MYC distintos del linfoma de Burkitt: comparación entre R-CHOP y la inmunoquimioterapia tipo Burkitt
Maria Joao Baptistaa, Gustavo Tapiab, José-Ángel Hernández-Rivasc, Alejandra Martínez-Trillosd, José-Luis Mateb, José-Tomás Navarroa,
Corresponding author

Corresponding author.
a Departamento de Hematología, Institut Català d’Oncologia (ICO)-Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain
b Departamento de Anatomía Patológica, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain
c Departamento de Hematología, Hospital Universitario Infanta Leonor, Universidad Complutense de Madrid, Madrid, Spain
d Departamento de Hematología, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Related content
Med Clin. 2017;149:343-410.1016/j.medcle.2017.05.029
Alejandro Martín García-Sancho
Article information
Full Text
Download PDF
Figures (1)
Tables (1)
Table 1. Main characteristics of patients with non-Burkitt lymphomas with MYC rearrangement, comparing single hit against double and triple hit lymphomas.
Background and objective

MYC-rearranged (MYC-R) lymphomas other than Burkitt lymphoma (BL) are very aggressive, with poor prognosis when treated with standard regimens. We aimed to study the characteristics and outcome of a series of MYC-R lymphomas comparing the treatment results between R-CHOP based and a specific intensive regimen for BL (BURKIMAB).

Patients and methods

Retrospective study of patients diagnosed with MYC-R. Translocations of MYC, BCL2 and BCL6 were evaluated by fluorescent in situ hybridization. Patients were treated with either, R-CHOP based immunochemotherapy or the Burkitt type regimen, BURKIMAB.


Thirty-four MYC-R lymphoma cases were studied: 21 treated with R-CHOP and 13 treated with BURKIMAB. There were no differences in CR rate; 45% (9/20) for R-CHOP and 42% (5/12) for BURKIMAB (p=0.99). Although overall survival (OS) and progression free survival (PFS) of BURKIMAB-treated patients were better than those of R-CHOP-treated (3y-OS: 46 vs. 24%; 3y-PFS: 46 vs. 10%), the differences were not statistically significant.


MYC-R lymphomas show poor outcomes even when treated with intensive immunochemotherapy for BL.

Antecedentes y objetivo

Los linfomas con reordenamiento de MYC (MYC-R) diferentes al linfoma de Burkitt (LB) son muy agresivos, con un pronóstico desfavorable cuando se tratan con regímenes estándar. El objetivo del estudio fue investigar las características y el resultado de una serie de linfomas MYC-R, comparando los resultados del tratamiento de los regímenes basados en R-CHOP y un régimen intensivo específico para LB (BURKIMAB).

Pacientes y métodos

Estudio retrospectivo de pacientes diagnosticados de MYC-R. Se evaluaron las translocaciones de MYC, BCL2 y BCL6 mediante hibridación in situ fluorescente. Se trató a los pacientes, bien con inmunoquimioterapia basada en R-CHOP, bien con el régimen tipo Burkitt, BURKIMAB.


Se estudiaron 34 casos de linfomas MYC-R: 21 tratados con R-CHOP y 13 tratados con BURKIMAB. No se produjeron diferencias en cuanto a tasa de RC; 45% (9/20) para R-CHOP y 42% (5/12) para BURKIMAB (p=0,99). Aunque la supervivencia global (SG) y la supervivencia libre de progresión (SLP) de los pacientes tratados con BURKIMAB fueron mejores que las de los pacientes tratados con R-CHOP (SG a 3 años: 46 frente a 24%; SLP a 3 años: 46 frente a 10%), las diferencias no fueron estadísticamente significativas.


Los linfomas MYC-R muestran resultados desfavorables, aun cuando se tratan con inmunoquimioterapia intensiva para LB.

Palabras clave:


These are the options to access the full texts of the publication Medicina Clínica (English Edition)

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Medicina Clínica (English Edition)

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos